Search

Displaying results 3621 - 3630 of 10000 in total
  1. Drug

    Cortisone acetate

    go.drugbank.com/drugs/DB01380
    ApprovedInvestigational

    Cortisone acetate was first isolate in 1935 and became more widely researched in 1949. … [A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107]

  2. Drug

    Amilomotide

    go.drugbank.com/drugs/DB05150
    Investigational

    CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. … It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.

  3. Drug

    Terconazole

    go.drugbank.com/drugs/DB00251
    Approved

    [FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels of safety, efficacy, and tolerability in clinical trials. … [A178096] Terconazole was initially approved by the FDA in 1987.

  4. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

    Mixtures: Darvocet-N 50, Darvocet-N 100Products: Darvon-N
  5. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission. … The vaccine is a polyvalent Wilms tumor gene 1 (WT1) peptide analog vaccine.

  6. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.

  7. Drug

    Flubendazole

    go.drugbank.com/drugs/DB08974
    ApprovedInvestigationalWithdrawn

    Flubendazole is an anthelmintic that is used to treat worm infection in humans. It is available OTC in Europe.

  8. Drug

    Eszopiclone

    go.drugbank.com/drugs/DB00402
    ApprovedInvestigational

    This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004. … One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia.

  9. Drug

    NBI-6024

    go.drugbank.com/drugs/DB05819
    Investigational

    NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.

  10. Drug

    CT-011

    go.drugbank.com/drugs/DB05916
    Investigational

    CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. … It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.